Small Molecule Combination Therapies Are Being Investigated to Increase Response Rates Researchers agree that now is a crucial time to be involved in hepatitis C virus (HCV) research. “Current ...

Findings showed that in patients treated with glecaprevir/pibrentasvir, the overall SVR12 rate was 96%, with 0 patients experiencing virologic failure. The Food and ...

The FDA is notifying health-care professionals about potential dangerous drug interactions between the hepatitis C virus (HCV) protease inhibitor boceprevir (Victrelis, Merck) and certain anti-HIV ...

"In patients with chronic infection with [HCV] genotype 1 who do not have a sustained response to therapy with peginterferon–ribavirin, outcomes after retreatment are suboptimal," write Bruce R. Bacon ...

AbbVie may have an edge over Gilead in the race to bring a faster-acting, all-oral hepatitis C cure to market, but it’s a slight one. Yesterday the drugmaker presented detailed Phase-III data for its ...

HANGZHOU, China & RESEARCH TRIANGLE PARK, NC & SAN FRANCISCO--(BUSINESS WIRE)--Ascletis and Presidio announced today that they have entered into an exclusive licensing agreement for Presidio’s ...

Patients treated with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) and antiretrovirals (ARVs) for HIV rarely receive drug combinations that are contraindicated, according to real-world ...

The new diabetes test helps identify patients with type 1 diabetes The FDA has approved Harvoni (ledipasvir/sofosbuvir; Gilead Sciences), the first once-daily single ...